Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Securities code: 2309 November 30, 2017

To our shareholders,

Kazuo Nakamura Chairman & CEO CMIC HOLDINGS Co., Ltd. 1-1-1 Shibaura, Minato-ku, Tokyo

# Notice of the Convocation of the 33rd Ordinary General Meeting of Shareholders

You are cordially invited to attend the 33rd Ordinary General Meeting of Shareholders of CMIC HOLDINGS Co., Ltd. (the "Company"), which will be held as described below.

If you are unable to attend the meeting, you may exercise your voting rights in writing or via the internet. Please review the attached "Reference Documents for the General Meeting of Shareholders" below to exercise your voting rights.

1. Date and time: Friday, December 15, 2017 at 10:00 a.m.

**2.** Place: Banquet hall "JOUR" (Main building 1st floor), Happo-en

1-1-1 Shirokanedai, Minato-ku, Tokyo

#### 3. Agenda:

## Matters to be reported:

- 1. Report on the business report, the consolidated financial statements for the 33rd fiscal year (from October 1, 2016 to September 30, 2017) and the results of the audit of the consolidated financial statements by the financial auditor and the Audit & Supervisory Board
- 2. Report on the non-consolidated financial statements for the 33rd fiscal year (from October 1, 2016 to September 30, 2017)

# Matters to be resolved:

Proposal 1: Election of Twelve (12) Directors

Proposal 2: Election of One (1) Audit & Supervisory Board Member

#### 4. Exercise of voting rights by proxy:

If you exercise your voting rights by proxy, you may designate one other shareholder holding voting rights in the Company to attend the meeting. Please note, however, that it is necessary to submit a document proving the authority of the proxy.

Any modifications to the Reference Documents for the General Meeting of Shareholders will be posted on the Company's website (https://www.cmicgroup.com; in Japanese only).

# **Reference Documents for the General Meeting of Shareholders**

# **Proposal 1:** Election of Twelve (12) Directors

At the conclusion of this Ordinary General Meeting of Shareholders, the terms of office of all thirteen (13) Directors will expire. In that regard, the Company proposes the election of twelve (12) Directors (three (3) of whom are outside Directors) including one (1) new candidate.

The candidates for Director are as follows:

Candidate No. 1	Reelection	Inside Director	Number of the Company's shares owned <b>552,620</b> shares	Attendance to meetings of the Board of Directors 12/12 (100%)		
	[Career summary, position and responsibility in the Company]					
	Apr. 1969	Apr. 1969 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)				
	Mar. 1992	Representative Director and President, the Company				
	Oct. 2003	Representative Director, Chairman and President CEO, the Company				
Kazuo Nakamura (December 17, 1946)	Dec. 2013	Representative Director, Chairman and President CEO, the Company (change of Japanese title only) (to present)				
	[Reasons fo	r nomination as ca	andidate for Director]			
	After working in research and development at a large pharmaceutical corporation, Mr. Kazuo Nakamura founded the Company. He possesses outstanding abilities in executive management, which he has used to steer the Company as a leading company. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Director.					
Candidate No. 2	Reelection	Inside Director	Number of the Company's shares owned <b>3,900</b> shares	Attendance to meetings of the Board of Directors 12/12 (100%)		
	[Career summary, position and responsibility in the Company]					
	Apr. 1974	Joined Fuji Photo	Film Co., Ltd. (currently FUJ	IFILM Corporation)		
	June 2009	Director & Corpo	rate Vice President, FUJIFILM	M Holdings Corporation		
	July 2014	Joined the Company, Senior Advisor of CMO Company				
	Oct. 2014	Senior Corporate Officer, CMO Company President, the Company				
	Dec. 2014	Director, Senior Corporate Officer and CMO Company President, the Company				
Nobuaki Inoue	May 2015	Director, Senior Executive Officer and CMO Company President, the Company				
(November 25, 1948)	Oct. 2016	Representative Director, Executive Vice President and CTO, the Company (to present)				
	[Reasons for nomination as candidate for Director]					
	With a long standing history of serving in important technology-related and manufacturing positions at a large manufacturing corporation, Mr. Nobuaki Inoue possesses insight relating to management. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Director.					

Candidate No. 3	Reelection	Inside Director	Number of the Company's shares owned <b>148,600</b> shares	Attendance to meetings of the Board of Directors 12/12 (100%)			
	[Career sur	nmary, position an	d responsibility in the Com	pany]			
	Apr. 1982	Joined Nikkei/McGraw-Hill Inc. (currently Nikkei Business Publications, Inc.)					
	Oct. 1989	Joined Genentech, Inc.					
	Jan. 1996	96 Joined the Company					
	July 2000	Director, the Com	pany				
	Oct. 2004	Oct. 2004 Director and Vice President, the Company					
	Dec. 2010	c. 2010 Representative Director, the Company					
	Apr. 2011	Representative Director, Corporate Officer, in charge of International Business, the Company					
	Dec. 2013		rector, Executive Vice Presideness Development Div., the C				
Keiko Nakamura (January 3, 1957)	Oct. 2016	Representative Director, Executive Vice President, CEO of CRO Business, Division Head of International Business Management Div., the Company (to present)					
	Significant o	concurrent positions	s outside the Company:				
	Chairperson	, CMIC Co., Ltd.					
	Representat	ve Director and Vio	ce President, CMIC ShiftZero	K.K.			
	President, A	RTEMIS Inc.					
	[Reasons fo	r nomination as ca	indidate for Director]				
	With extensive experience at international corporations, Ms. Keiko Nakamura is in charge of international business development, which is instrumental in the Company's globalization, and she possesses outstanding abilities in executive management. As the Company expects her to continue to perform a decision-making and supervisory role in management, it again nominated her as a candidate for Director.						
Candidate No. 4	Reelection	Inside Director	Number of the Company's shares owned <b>2,500</b> shares	Attendance to meetings of the Board of Directors 12/12 (100%)			
	[Career sur	nmary, position an	d responsibility in the Com	pany]			
	Apr. 1985	Joined Nippon Oi	1 & Fats Co., Ltd. (currently N	NOF CORPORATION)			
	Jan. 1997	Joined Allied Tele	esis Holdings K.K.				
	Aug. 2005	Joined the Compa	iny				
	Oct. 2010	Corporate Officer, in charge of Internal Control/Information Disclosure/Finance and Accounting, the Company					
	Dec. 2010	Director, the Com	pany				
XX7 / X/F 1 · 1 ·	Oct. 2012	Director, Corporate Officer and CFO, in charge of Internal Control/Information Disclosure, the Company					
Wataru Mochizuki (December 10, 1961)	Oct. 2013	Director, Senior Corporate Officer and CFO, in charge of Finance and Legal Affairs Department/Internal Control/Information Disclosure, the Company					
	May 2015	Director, Senior Executive Officer and CFO, in charge of Internal Control/Information Disclosure, the Company (to present)					
	[Reasons for nomination as candidate for Director]						
	With extensive knowledge and experience in administrative departments, Mr. Wataru Mochizuki possesses outstanding abilities in executive management. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Director.						

Candidate No. 5	Reelection	Inside Director	Number of the Company's shares owned <b>1,800</b> shares	Attendance to meetings of the Board of Directors <b>10/10</b> (100%)		
	[Career summary, position and responsibility in the Company]					
	Apr. 1984	Joined Akiyama	Inc. (currently SUZUKEN CO	)., LTD.)		
	Oct. 1989	Joined Baxter Lin	mited			
	June 1999	Joined Starbucks	Coffee Japan, Ltd.			
	Apr. 2007 Joined Quintiles Transnational Japan K.K.					
	Jan. 2012	Joined the Company, Corporate Officer, in charge of Corporate Planning/ IPD				
	Dec. 2012	Director, Corporate Officer and IPD Company President, the Company				
	May 2015	Senior Executive the Company	Officer, in charge of Business	Development,		
	Oct. 2016	Senior Executive	Officer, in charge of Business	Development,		
Makoto Matsukawa		CEO of CDMO I	Business, the Company (to pre-	sent)		
(March 30, 1960)	Dec. 2016	Director, the Con	npany (to present)			
	Significant o	concurrent position	s outside the Company:			
	Representati	ive Director & CEO	O, CMIC CMO Co., Ltd.			
	Representati	ive Director, CMIC	C Ashfield Co., Ltd.			
	[Reasons for nomination as candidate for Director]					
			various industry sectors inclu			
	pharmaceutical sector, but also large-player service sector, Mr. Makoto Ma possesses management experience and plays an instrumental role in globa strategic business development within the Company. As the Company exp continue to perform a decision-making and supervisory role in management nominated him as a candidate for Director.					
	•					
Candidate No. 6	Reelection	Inside Director	Number of the Company's shares owned <b>2,000</b> shares	Attendance to meetings of the Board of Directors <b>10/10</b> (100%)		
	[Career sun	nmary, position a	nd responsibility in the Comp	pany]		
	Apr. 1984	Joined Sankyo Co	o., Ltd. (currently Daiichi Sanl	kyo Co., Ltd.)		
	June 2004	General Manager	of Clinical Development Dep	artment, Sankyo Co., Ltd.		
	Feb. 2016	Joined the Compa	any, Senior Corporate Officer			
	Director and Executive Vice President, CMIC Co., Ltd.					
	Oct. 2016		Co., Ltd. (to present)			
	Dec. 2016	Director and Sen	ior Executive Officer, the Com	npany (to present)		
Toru Fujieda	~ .		~			
(November 8, 1959)	Significant concurrent positions outside the Company:					
	President, CMIC Co., Ltd.  [Reasons for nomination as candidate for Director]					
	With extensive experience in clinical development and management experience large pharmaceutical corporation, Mr. Toru Fujieda plays an instrumental role in CRO business for the Company. As the Company expects him to continue to per decision-making and supervisory role in management, it again nominated him as candidate for Director.					

Candidate No. 7	Reelection	Inside Director	Number of the Company's shares owned 1,500 shares	Attendance to meetings of the Board of Directors <b>10/10</b> (100%)		
	[Career sun	nmary, position an	d responsibility in the Comp	pany]		
	Apr. 1991	Apr. 1991 Joined Roussel Uclaf S.A.				
	Sept. 1995	1995 Joined Hoechst Marion Roussel Japan Ltd.				
	Aug. 2004	g. 2004 Joined Sanofi-aventis K.K. (currently Sanofi K.K.)				
	Apr. 2005	Joined GlaxoSmit	hKline K.K.			
	Apr. 2012	Corporate Officer and General Manager of Business Innovation Division, GlaxoSmithKline K.K.				
	Nov. 2014	Representative Di	rector and President, Aspen Ja	apan K.K.		
	July 2016	Joined the Compa	ny, Senior Executive Officer	(to present)		
Auvaro Philippe Henri		President, Orphan	Pacific, Inc. (to present)			
(August 24, 1964)	Dec. 2016	Director, the Com	pany (to present)			
		concurrent positions rphanPacific, Inc.	outside the Company:			
	[Reasons for nomination as candidate for Director] With management experience at the commercial planning department and overseas affiliates in large pharmaceutical corporations, Mr. Auvaro Philippe Henri plays an instrumental role in globalization of the Company and the establishment of new business models. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Director.					
Candidate No. 8	Reelection	Inside Director	Number of the Company's shares owned <b>1,000</b> shares	Attendance to meetings of the Board of Directors <b>10/10</b> (100%)		
	[Career sun	nmary, position an	d responsibility in the Comp	pany]		
	Apr. 1985	Joined ICI Pharma	a K.K. (currently AstraZeneca	K.K.)		
	Apr. 2011	Joined Quintiles T	Fransnational Japan K.K.			
	May 2012	Joined the Compa	ny			
	Oct. 2012 Corporate Officer and CHO, General Manager of Strategy Human Resources Department, the Company					
	Oct. 2013	Senior Corporate Officer and CHO, in charge of Strategy Human Resources Department, the Company				
Yoshiyuki Hano (September 8, 1961)	Apr. 2016	6 Senior Corporate Officer and CHO, in charge of Human Resources and General Affairs, the Company				
, ,	Dec. 2016 Director, Senior Executive Officer and CHO, in charge of Human Resources and General Affairs, the Company (to present)					
	[Reasons for nomination as candidate for Director]					
	Possessing extensive human-resource related experience, particularly in organizational development at large pharmaceutical corporations, Mr. Yoshiyuki Hano plays an instrumental role in the Company's human-resource strategy. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Director.					

Candidate No. 9	New election	Inside Director	Number of the Company's shares owned <b>23,100</b> shares	Attendance to meetings of the Board of Directors –		
	[Career sum	[Career summary, position and responsibility in the Company]				
	Apr. 1986	Joined Kotai Kasei Co., Ltd. (currently TAIHO PHARMACEUTICAL CO., LTD.)				
	July 1993	Joined the Company				
	Apr. 2008	Director and Vice President, CMIC Korea Co., Ltd.				
	Nov. 2009	Corporate Officer, Division Head of Business Development Div., the Company				
	Feb. 2013	President, CMIC-PMS Co., Ltd.				
	Oct. 2014	President, CMIC Bioresearch Center Co., Ltd. (currently CMIC Pharma Science Co., Ltd.)				
	May 2015 Senior Corporate Officer, the Company (to present)					
Akihisa Mitake (October 24, 1963)	Oct. 2016 President, Site Support Institute Co., Ltd. (to present)					
	Significant concurrent positions outside the Company:					
	President, Site Support Institute Co., Ltd.					
	[Reasons for nomination as candidate for Director]					
	After accumulating development experience at a pharmaceutical corporation, Mr. Akihisa Mitake has engaged in numerous positions at the Company over many years since its initial founding period and served in important positions at the Company's subsidiaries since 2008, contributing to the continual growth of businesses he was responsible for. As the Company expects him to perform a decision-making and supervisory role in management based on his extensive experience and achievements in the Company's business, it has newly nominated him as a candidate for Director.					

Candidate No. 10	Reelection	Outside Director	Number of the Company's shares owned – shares	Attendance to meetings of the Board of Directors 12/12 (100%)	
	[Career summary, position and responsibility in the Company]				
	Apr. 1968	Apr. 1968 Joined The Sanwa Bank, Ltd. (currently The Bank of Tokyo-Mitsubishi UFJ, Ltd.)			
	June 1994 Director, The Sanwa Bank, Ltd.				
	May 1997	Managing Directo	or, The Sanwa Bank, Ltd.		
	June 1999 President, Sanwa Capital Finance Ltd. (currently Mitsubishi UFJ Capital Co., Ltd.)				
	June 2005	Chairman and Dir	ector, Ask Planning Center, I	nc.	
	July 2005	Chairman, CREE	K & RIVER Co., Ltd.		
	Mar. 2011	President, Medica	l Principle Co., Ltd. (to prese	ent)	
	Dec. 2014	Outside Director,	the Company (to present)		
	June 2017	Chairman and Dia	rector, ASK HOLDINGS, INC	C. (to present)	
Akira Nakamura (December 24, 1944)	June 2017	Chairman and Dir	rector, Wealth Management, I	nc. (to present)	
	0 0	•	s outside the Company:		
		Medical Principle Co			
		nd Director, ASK H			
	Chairman ai	nd Director, Wealth	Management, Inc.		
	-		andidate for outside Directo	-	
	possesses ex expects him advising and and objective	tensive experience to utilize this expert d supervising its over	serving in corporate manager and insight as a corporate ma- rience and insight to continue erall management from the pe- ing of the Company's Board of the corporate of the corp	nager. As the Company fulfilling the role of erspective of effectiveness	
	nonmated i	iiii us u cuitatatte i	or outside Director.		
	1		Number of the Company's	Attendance to meetings	
Candidate No. 11	Reelection	Outside Director	shares owned - shares	of the Board of Directors 12/12 (100%)	
	[Career sur	nmary, position an	d responsibility in the Com	pany]	
	Apr. 1972	Joined ITOCHU	Corporation		
	June 1989	Seconded to Niho CORPORATION	n Parking Card K.K. (current)	ly NIHON PARKING	
		Representative Di	rector, Nihon Parking Card K	C.K.	
	Apr. 1994	President, Nihon	Parking Card K.K.		
	Mar. 2000	Representative Di	rector, NIHON PARKING C	ORPORATION	
	May 2011	Chairman of the I	Board of Directors, NIHON P.	ARKING CORPORATION	
	Oct. 2013	President and Rep	presentative Director, IPI Co.,	LTD. (to present)	
Shinji Kobayashi (July 31, 1948)	Dec. 2015	Outside Director,	the Company (to present)		
	Significant of	concurrent positions	s outside the Company:		
	irector, IPI Co., LTD.				
	[Reasons for nomination as candidate for outside Director]				
	After joining establishmen experience a managemen	g a large trading con nt of a growth platform and such achieveme t. As the Company	poration, Mr. Shinji Kobayas orm as a corporate manager fonts, he possesses outstanding expects him to continue fulfil nent, it again nominated him	hi was instrumental in the or a start-up. With this abilities in executive ling the role of advising and	

Candidate No. 12	Reelection	Outside Director	Number of the Company's shares owned – shares	Attendance to meetings of the Board of Directors <b>9/10</b> (90%)		
	[Career sur	nmary, position an	d responsibility in the Comp	pany]		
	Dec. 1973	Joined Department of Surgery II, The University of Tokyo Hospital				
	Apr. 1983	Joined Department of Surgery II, Faculty of Medicine, University of Yamanashi				
	Apr. 1993	Joined Hoechst Ja	pan Co., Ltd.			
	Jan. 2005	Joined GlaxoSmit	hKline K.K.			
	Sept. 2011	Specially Appointed Professor, Department of Clinical Research, Faculty of Medicine, University of Yamanashi				
	Sept. 2014	Specially Appointed Professor, Department of Advanced Biomedical Research, Faculty of Medicine, University of Yamanashi (to present)				
	Apr. 2015	Vice President, University of Yamanashi (to present)				
Masaru Iwasaki (May 3, 1947)	Dec. 2016	Outside Director,	the Company (to present)			
(May 5, 1717)	Significant concurrent positions outside the Company:					
	Vice President, University of Yamanashi					
	Program Officer, Japan Agency for Medical Research and Development					
	Visiting Pro	fessor, Juntendo Un	iversity School of Medicine			
	[Reasons for nomination as candidate for outside Director]					
	After working as a clinician in the oncology area, Mr. Masaru Iwasaki possesses experience and achievements from serving in important positions for large pharmaceutical corporations in areas including product strategy planning and product development. As the Company expects him to continue fulfilling the role of advising and supervising its overall management, it again nominated him as a candidate for outside Director.					

Notes:

- 1. There is no special interest between any of the candidates and the Company.
- 2. Mr. Akira Nakamura, Mr. Shinji Kobayashi and Mr. Masaru Iwasaki are candidates for outside Director.
- 3. Mr. Akira Nakamura is currently an outside Director of the Company, and at the conclusion of this meeting, his tenure as outside Director will have been three (3) years.
- 4. Mr. Shinji Kobayashi is currently an outside Director of the Company, and at the conclusion of this meeting, his tenure as outside Director will have been two (2) years.
- 5. Mr. Masaru Iwasaki is currently an outside Director of the Company, and at the conclusion of this meeting, his tenure as outside Director will have been one (1) year.
- 6. The Company has entered into an agreement with Mr. Akira Nakamura, Mr. Shinji Kobayashi and Mr. Masaru Iwasaki to limit their liability amount to the minimum liability amount as provided for by Article 425, paragraph 1 of the Companies Act. If their reelection is approved, the Company plans to continue said limited liability agreement with each one of them.
- 7. The Company has submitted notification to the Tokyo Stock Exchange that Mr. Akira Nakamura, Mr. Shinji Kobayashi and Mr. Masaru Iwasaki have been appointed as independent officers as provided for by the aforementioned exchange. If their reelection is approved, the Company plans for their appointments as independent officers to continue.

# Proposal 2: Election of One (1) Audit & Supervisory Board Member

The Company proposes the election of one (1) Audit & Supervisory Board Member, increasing the number of outside Audit & Supervisory Board Members by one (1) to strengthen the audit system.

The consent of the Audit & Supervisory Board has been obtained for this proposal.

The candidate for Audit & Supervisory Board Member is as follows:

	New election C	Outside Audit & Supervisory Board Member	Number of the Company's shares owned – shares				
	[Career summ	ary and position in the Company]					
	Oct. 1981	Joined Nomura Research Institute, Ltd.	Joined Nomura Research Institute, Ltd.				
	Sept. 1985	Management Consultant, McKinsey & Company					
	Oct. 1986	Fund Manager, Mercury Asset Management plc, SG Warburg					
	Nov. 1995	Chief Investment Officer (CIO), Yamaichi	Regent ABC Polska				
	July 1998	Joined Bank for International Settlements					
	Oct. 2004	ct. 2004 Senior Pension Fund Administrator, Organisation for Economic Co-operation and Development (OECD)					
	Mar. 2008	Representative, Kawai Global Intelligence					
	Apr. 2012	cellence in Higher Education,					
	Apr. 2013	Professor, Institute for Liberal Arts and Sci	ences, Kyoto University				
Eriko Kawai (April 28, 1958)	Apr. 2014	Professor, Graduate School of Advanced In Survivability, Kyoto University (to present)	_				
	Significant cond	current positions outside the Company:					
	Professor, Grad University	Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University					
	Director, The C	outlook Foundation					
	Director, The G	Frew Bancroft Foundation					
	Outside Directo	side Director, Nikko Asset Management Co., Ltd.					
	[Reasons for n	omination as candidate for outside Audit & S	upervisory Board Member]				
	possesses exper management. A	er extensive experience in international corporate ience and achievements as a corporate manager as the Company expects her to fulfill the role of inated her as a candidate for outside Audit & Su	and outstanding knowledge in auditing at the Company, it				

Notes:

- 1. There is no special interest between the candidate and the Company.
- 2. Ms. Eriko Kawai is a candidate for outside Audit & Supervisory Board Member.
- 3. If the election of Ms. Eriko Kawai is approved, pursuant to the provisions of Article 427, paragraph 1 of the Companies Act, the Company plans to enter into an agreement with her to limit her liability for damages under Article 423, paragraph 1 of the same Act. The maximum amount of liability for damages under this agreement is the minimum liability amount provided for by Article 425, paragraph 1 of the same Act.
- 4. Ms. Eriko Kawai satisfies the requirements for an independent officer as provided for by the Tokyo Stock Exchange, and if her election is approved, the Company plans to designate her as an independent officer.